Angiotensin II-forming pathways in normal and failing human hearts
- PMID: 2156635
- DOI: 10.1161/01.res.66.4.883
Angiotensin II-forming pathways in normal and failing human hearts
Abstract
Reduced preload and afterload to the heart are important effects of angiotensin converting enzyme (ACE) inhibitors in the treatment of congestive heart failure. However, since angiotensin II (Ang II) directly increases the strength of myocardial contraction, suppression of Ang II formation by ACE inhibitors could potentially reduce the beneficial effects of Ang II on the failing heart. To study how ACE inhibition suppresses cardiac Ang II formation in man, we characterized ACE-dependent and ACE-independent Ang II-forming pathways in eight normal and 24 failing human hearts obtained at cardiac transplantation. Ang II-forming activity in left ventricular (LV) membrane preparations was assessed by measuring the conversion of [125I]angiotensin I (Ang I) to [125I]Ang II. LV [125I]Ang II-forming activity in normal hearts (35.5 +/- 2.7 fmol/min/mg, n = 8) was not different from that in hearts from patients with ischemic cardiomyopathy (25.5 +/- 2.9 fmol/min/mg, n = 9) and was 48% lower (p less than 0.001) in hearts from patients with idiopathic cardiomyopathy (18.5 +/- 1.9 fmol/min/mg, n = 15).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2.Circulation. 2003 Oct 7;108(14):1707-12. doi: 10.1161/01.CIR.0000094734.67990.99. Epub 2003 Sep 22. Circulation. 2003. PMID: 14504186
-
Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway.J Clin Invest. 1995 Sep;96(3):1490-8. doi: 10.1172/JCI118186. J Clin Invest. 1995. PMID: 7657820 Free PMC article.
-
Angiotensins and the failing heart. Enhanced positive inotropic response to angiotensin I in cardiomyopathic hamster heart in the presence of captopril.Circ Res. 1990 Apr;66(4):891-9. doi: 10.1161/01.res.66.4.891. Circ Res. 1990. PMID: 2180588
-
Tissue angiotensin II system in the human heart.Eur Heart J. 1994 Dec;15 Suppl D:68-78. doi: 10.1093/eurheartj/15.suppl_d.68. Eur Heart J. 1994. PMID: 7713117 Review.
-
Cardiac angiotensin II formation: the angiotensin-I converting enzyme and human chymase.Eur Heart J. 1993 Nov;14 Suppl I:177-82. Eur Heart J. 1993. PMID: 8293772 Review.
Cited by
-
Start of therapy with the angiotensin II antagonist losartan after immediate switch from pretreatment with an ACE inhibitor.Br J Clin Pharmacol. 1998 Aug;46(2):169-72. doi: 10.1046/j.1365-2125.1998.00753.x. Br J Clin Pharmacol. 1998. PMID: 9723827 Free PMC article. Clinical Trial.
-
Acidic urine is associated with poor prognosis in patients with chronic heart failure.Heart Vessels. 2013 Nov;28(6):735-41. doi: 10.1007/s00380-012-0312-z. Epub 2012 Dec 30. Heart Vessels. 2013. PMID: 23274576
-
Risks and benefits of the treatment of heart failure. Current status.Drug Saf. 1991 Jul-Aug;6(4):277-84. doi: 10.2165/00002018-199106040-00005. Drug Saf. 1991. PMID: 1888443 Review.
-
Heart failure therapy at the turn of the century.Heart Fail Rev. 2001 Jan;6(1):7-14. doi: 10.1023/a:1009847006280. Heart Fail Rev. 2001. PMID: 11248763 Review.
-
Is chymase 1 a therapeutic _target in cardiovascular disease?Expert Opin Ther _targets. 2023 Jul-Dec;27(8):645-656. doi: 10.1080/14728222.2023.2247561. Epub 2023 Aug 21. Expert Opin Ther _targets. 2023. PMID: 37565266 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
